Laure Cosson
Tours, 37044, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
Beyond Trikafta: new models to assess tissue dependent rescue of N1303K-CFTR.
Journal: Frontiers in pharmacology
Published: July 07, 2025
D e novo SRRM2 variants in neuroendocrine cell hyperplasia of infancy and persistent tachypnoea of infancy.
Journal: The European respiratory journal
Published: April 11, 2025
Sweat chloride and lung function responses to elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis with two versus one responsive CFTR variants: an analysis of two real-world observational studies.
Journal: The Lancet. Respiratory medicine
Published: March 27, 2025
Effect of Elexacaftor/Tezacaftor/Ivacaftor on Glucose Tolerance in Adolescents With Cystic Fibrosis.
Effect of Elexacaftor/Tezacaftor/Ivacaftor on Glucose Tolerance in Adolescents With Cystic Fibrosis.
Journal: The Journal of clinical endocrinology and metabolism
Published: August 02, 2024
The expanded French compassionate programme for elexacaftor-tezacaftor-ivacaftor use in people with cystic fibrosis without a F508del CFTR variant: a real-world study.
Journal: The Lancet. Respiratory medicine
Published: April 11, 2024
Pulmonary mucoepidermoid carcinoma in a 7-year-old child.
Journal: Pediatric pulmonology
Published: December 13, 2023
Theratyping cystic fibrosis patients to guide elexacaftor/tezacaftor/ivacaftor out-of-label prescription.
Journal: The European respiratory journal
Published: January 18, 2023
The French compassionate programme of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with advanced lung disease and no F508del CFTR variant.
Journal: The European respiratory journal
Published: December 20, 2022
Advent of elexacaftor/tezacaftor/ivacaftor for cystic fibrosis treatment: What consequences on Aspergillus-related diseases? Preliminary insights.
Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
Published: June 27, 2022
Reclassifying inconclusive diagnosis for cystic fibrosis with new generation sweat test.
Journal: The European respiratory journal
Published: January 28, 2022
Using chest computed tomography and unsupervised machine learning for predicting and evaluating response to lumacaftor-ivacaftor in people with cystic fibrosis.
Journal: The European respiratory journal
Published: May 11, 2021
Effect of one-year lumacaftor-ivacaftor treatment on glucose tolerance abnormalities in cystic fibrosis patients.
Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
Published: October 15, 2019
Last Updated: 09/26/2026